

CGTP SUMMIT 2026



KNOWLEDGE SHARING AND CAPACITY BUILDING

- To move from patient speculation to specification, the *key element is to understand the product*.
- There is an increased need to have *patient-based/patient-centered specifications*.
- Specifications should *link product attributes to clinical outcomes through mechanistic understanding*. We're in the mechanistic age.
- While you may not know all the answers, you need a good plan (a map) to determine *what evaluations should be performed* and the various pieces of the robust specification puzzle.
- The *dynamic and multileveled specification understanding is necessary*, including characterization vs. release, potency matrix, product lifecycle, and global similarities/differences.
- In autologous CAR-T, out-of-specification (OOS) batches are an intrinsic challenge: we need to *focus on understanding, prevention, and reconsiderations*.

CGTP Summit 2026 BY THE NUMBERS



**Total
Attendees**

226



**First-Time
Attendees**

105



**Companies
Represented**

71



**Regulatory
Participation**

17



Countries Collaborated

14

Austria | Belgium | Canada | China | Denmark | Germany | Ireland | Italy | Japan | Netherlands | Spain | Sweden | United Kingdom | United States

CASSS RESOURCES

Looking for more past meeting content?

Speaker slides, roundtable notes, and video presentations can be accessed through **Papers and Presentations** and **CASSS On Demand** on our website. www.casss.org

